[CAS NO. 144055-55-0]  FK706

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [144055-55-0]

Catalog
HY-19269
Brand
MCE
CAS
144055-55-0

DESCRIPTION [144055-55-0]

Overview

MDL-
Molecular Weight592.54
Molecular FormulaC26H32F3N4NaO7
SMILESO=C(NC(C(C)C)C(C(F)(F)F)=O)[C@H]1N(C([C@H](C(C)C)NC(C2=CC=C(C(NCC(O[Na])=O)=O)C=C2)=O)=O)CCC1

For research use only. We do not sell to patients.

Summary

FK706 is a potent, slow-binding and competitive inhibitor of human neutrophil elastase with an IC 50 of 83 nM and a K i of 4.2 nM. FK706 also inhibits mouse neutrophil elastase and porcine pancreatic elastase with IC 50 s of 22 nM and 100 nM, respectively, and has no inhibitory activity against other serine proteinases such as human pancreatic trypsin, human pancreatic α-chymotrypsin and human leukocyte cathepsin G. FK706 has anti-inflammatory effect [1] [2] .


IC50 & Target

IC50: 83 nM (Human neutrophil elastase), 22 nM (Mouse neutrophil elastase) and 100 nM (Porcine pancreatic elastase) [1] ;
Ki: 4.2 nM (Human neutrophil elastase) [1]


In Vitro

FK706 effectively inhibits the hydrolysis of bovine neck ligament elastin (2 mg/mL final concentration) by human neutrophil elastase (4 μg/mL final concentration) with an IC50 value of 230 nM [1] .
FK706 blocks the release of inflammatory chemokines, suppresses the expression of IL-8 and MCP-1 mRNA, and suppresses NF-κB activation. It seems possible that FK706 may directly blocks human lung fibroblasts activation of NF-κB, preventing expression of inflammatory chemokines during cigarette smoke–induced lung inflammation [2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

FK706 (10-100 mg/kg; subcutaneous injection; for 1-6 hours; male C57BL mice) treatment significantly suppresses human neutrophil elastase (20 μg/paw)-induced paw edema in mice in a dose-dependent manner (47% inhibition at a dose of 100 mg/kg) [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL mice (6 weeks old) injected with human neutrophil elastase [1]
Dosage: 10 mg/kg, 32 mg/kg, 100 mg/kg
Administration: Subcutaneous injection; for 1 hour, 2 hours, 4 hours, 6 hours
Result: Significantly suppressed human neutrophil elastase-induced paw edema in mice in a dose-dependent manner.

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)


Solvent & Solubility

In Vitro:

DMSO : 115 mg/mL ( 194.08 mM ; Need ultrasonic)

H 2 O : ≥ 100 mg/mL ( 168.76 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.6876 mL 8.4382 mL 16.8765 mL
5 mM 0.3375 mL 1.6876 mL 3.3753 mL
10 mM 0.1688 mL 0.8438 mL 1.6876 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 5 mg/mL (8.44 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 5 mg/mL (8.44 mM); Clear solution

  • 3.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 5 mg/mL (8.44 mM); Clear solution

* All of the co-solvents are available by MCE.